ClinicalTrials.gg
RecruitingNCT06324266Updated Mar 21, 2024

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

A Phase 2/3 interventional study of Cyclophosphamide and Lenalidomide in Newly Diagnosed Multiple Myeloma, sponsored by Jinling Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Jinling Hospital, China · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Apr 2023, registered Mar 2024).
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.

Planned enrollment
44th of 167
80 · median 41
Started
2023
with 3 others
Phase 2/3
4 of 171
1 open now
Primary completion
2025-12
later than 6 of 26 live
Registered
166th of 171
by date

Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 44th largest by planned enrollment of the 167 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 2/3, reaches primary completion later than 6 of the 26 other live ones, and was the 166th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies testing cyclophosphamide in Multiple Myeloma, or all of them as a file.
02

Study summary

The investigators will conduct randomized and controlled clinical studies in order to preliminarily explore the efficacy and safety of low-dose cyclophosphamide and lenalidomide in maintenance therapy for MM that is not suitable for transplantation in the standard-risk group.

Read the detailed description

The investigators will conduct randomized and controlled clinical studies to preliminarily explore the efficacy and safety of low-dose cyclophosphamide in maintenance therapy for MM that is not suitable for transplantation in the standard -risk group. Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy will use cyclophosphamide or lenalidomide as maintain therapy for 2 years.

03

Conditions studied

  • Newly Diagnosed Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. After induction and consolidation therapy (8 courses of chemotherapy), MM patients in the standard-risk group who were initially unsuitable for transplantation achieved a therapeutic effect of VGPR or above;
  2. Secretory MM with measurable indicators;
  3. Age ≥ 18 years old, gender unlimited;
  4. No obvious dysfunction of heart, lungs, etc. (≤ Grade I);
  5. General ≥ 70% (excluding those caused by pathological fractures and bone pain).

Exclusion criteria

Exclusion Criteria:

  1. Cytogenetic high-risk patients;
  2. Recurrent or MM;
  3. Using hematopoietic stem cell transplantation as a consolidation therapy;
  4. The therapeutic effect did not reach VGPR or above before enrollment;
  5. Asymptomatic MM;
  6. No measurable indicators;
  7. \<50%(excluding those caused by pathological fractures);
  8. Dysfunction of heart, lungs, etc. (> Grade I);
  9. Unable to cooperate in observing adverse reactions and therapeutic effects;
  10. Pregnancy, breastfeeding, or refusal of by women;
  11. There is drug abuse and medical, psychological, or social conditions that may interfere with patients participating in research or evaluating research results;
  12. Any unstable or potentially endangering patient safety and compliance with the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    arm CTX

    Cyclophosphamide monotherapy: CTX, 0.1g×7days,1/every other week, 28 days per course of treatment,total two years

    Drug: Cyclophosphamide

  • Placebo comparator
    arm Len

    Lenalidomide monotherapy:Len,10mg/day×21days, 28 days per course of treatment,total two years

    Drug: Lenalidomide

Interventions

  • Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.

    Also known as: CTX

  • DrugLenalidomide

    Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.

    Also known as: Len

06

What researchers measure

Primary outcomes

  1. PFS1

    Progression-free Survival 1

    Time frame: 3 years

Secondary outcomes

  1. Incidence of Efficacy as assessed by IMWG

    Efficacy assessed by IMWG

    Time frame: 3 years

  2. Incidence of Safety as assessed by CTCAE 4.0

    Safety assessed by CTCAE 4.0

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Dec 2025, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 21, 2024
StartActual
Apr 16, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06324266
Responsible party
Feng Li (Clinical Professor, Jinling Hospital, China) — Principal investigator
First posted
Mar 21, 2024
Start date
Apr 16, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 21, 2024

Study contacts

Zhao Qian
Contact
540598707@qq.com
18251835035
Li Feng, Doctor
principal investigator · Department of Hematology of Jinling Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion